The acceptance of the BLA resubmission by the FDA is a significant regulatory milestone for Abeona Therapeutics. It indicates progress in the approval process for pz-cel, which could lead to future revenue streams if approved. The set PDUFA date provides a timeline for investors to anticipate potential approval, likely boosting investor confidence and positively impacting the stock price in the short term.